VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KYMR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KYMRKymera Therapeutics, Inc.
$121.13$10.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksKYMRCash Flow

Kymera Therapeutics, Inc. (KYMR) Cash Flow Statement

8Y historyFree accessUpdated daily

Operating cash flow has been negative in every recent quarter, with free cash flow of -$78.2M in 2026Q3, and zero dividends or buybacks indicate all capital is retained to fund research operations.

Income StatementBalance SheetCash FlowRatios

KYMR Cash Flow Statement

Annual statement

KYMR Cash Flow Statement

Kymera Therapeutics, Inc. (KYMR) cash flow statement — 8-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations-287.56M-232.89M-194.5M-102.83M-153.09M-128.95M88.13M17.91M-17.86M
Operating CF Margin %--594.11%-413.2%-130.84%-326.92%-177.05%258.95%610.26%-
Operating CF Growth %-197.95%-19.74%-89.16%32.83%-18.72%-246.31%392.21%200.24%-
Net Income-349.47M-311.35M-223.86M-146.96M-154.81M-100.22M-45.59M-41.25M-21.47M
Depreciation & Amortization8.11M8.31M7.37M3.56M2.98M2.4M1.76M825K205K
Stock-Based Compensation68.23M59.9M55.01M43.12M35.48M24.97M5.19M1.2M648K
Deferred Taxes0000001.57M00
Other Non-Cash Items-8.71M-5.02M-9.06M-11.8M889K5.83M332K54.34M443K
Working Capital Changes-5.77M15.27M-23.97M9.25M-37.62M-61.92M124.87M2.79M2.31M
Change in Receivables0947K17.82M-16.23M-2.4M577K-577K0-148K
Change in Inventory00002.4M8.71M6.88M00
Change in Payables6.42M-1.97M-307K0253K54K990K0824K
Cash from Investing-415.56M-521.06M-404.08M139.89M20.52M-99.83M-422.59M-16.49M-1.36M
Capital Expenditures-1.33M-1.45M-12.84M-34.48M-2.84M-1.6M-9.1M-532K-1.36M
CapEx % of Revenue1.3%3.7%27.27%43.87%6.06%2.19%26.73%18.13%-
Acquisitions0000-20.52M5.81M413.49M00
Investments---------
Other Investing4.78M8.88M13.98M174.37M20.52M-5.81M-413.49M-15.95M0
Cash from Financing963.97M990.71M608.85M4.19M153M250.28M289.26M34.91M52.93M
Debt Issued (Net)-2.15M-1.49M-1.58M-76K-1.13M-849K-554K-371K-295K
Equity Issued (Net)965.69M992.21M596.62M0149.82M243.11M289.65M053.23M
Dividends Paid000000000
Share Repurchases000000000
Other Financing425K013.81M4.27M4.3M8.02M162K35.28M0
Net Change in Cash260.85M236.76M10.27M41.25M20.43M21.5M-45.2M36.33M33.71M
Free Cash Flow-288.89M-234.34M-207.34M-137.31M-155.92M-130.54M79.03M17.37M-19.22M
FCF Margin %-282.61%-597.81%-440.47%-174.71%-332.98%-179.24%232.22%592.13%-
FCF Growth %-25.49%-13.02%-51.01%11.94%-19.44%-265.17%354.92%190.39%-
FCF per Share-2.89-2.78-2.76-2.35-2.89-2.721.770.39-0.43
FCF Conversion (FCF/Net Income)0.83x0.75x0.87x0.70x0.99x1.29x-1.93x-0.43x0.83x
Interest Paid-19K00162K00046K0
Taxes Paid000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Persistent operating cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Losses Paired With Cash Burn Pattern

According to reported figures, KYMR's operating cash flow has been negative in every one of the last nine quarters, with OCF/NI ratios ranging from 0.33 to 1.28, indicating that losses are being converted into cash outflows rather than being masked by non-cash charges.

Because net losses are largely matched by operating cash outflows, the earnings-quality question is less about accruals and more about the absolute size of the burn. The OCF/NI ratio above 1.0 in several quarters, such as 2026Q1 at 1.28, suggests working capital movements or timing effects temporarily amplified cash outflows beyond reported losses. Investors should monitor whether the ratio normalizes, as sustained OCF exceeding net loss would warrant further investigation into working capital drains.

Free Cash Flow Deficits Widen Into 2026

Based on KYMR's reported figures, free cash flow turned to -$89.3M in 2026Q1 from -$27.3M in 2025Q3, with the latest quarter at -$78.2M, showing that the cash deficit has persisted at a much larger scale than the 2024 levels.

FCF margins are deeply negative and not meaningful as a profitability gauge given the lumpy revenue base, but the absolute burn is the decisive metric. Capital expenditure is negligible, so nearly all of the deficit is operating in nature, consistent with clinical-stage research spending. The trend suggests the cash runway is shaped by operating cost discipline rather than capital allocation choices.

Working Capital Swings Drive Quarterly Volatility

As reported in financial statements, KYMR's working capital change swung from a $38.5M inflow in 2025Q3 to a $34.9M outflow in 2026Q1, with the latest quarter showing a $34.8M outflow, making quarterly cash conversion unusually volatile.

The magnitude of working capital swings relative to net loss suggests collaboration receivables and deferred revenue timing, rather than inventory or payables dynamics, are the primary drivers. Such swings make single-quarter operating cash flow a weak indicator of the underlying burn rate. Analysts should focus on trailing multi-quarter averages to avoid misreading timing effects as structural change.

No Shareholder Returns Amid Burn

According to SEC-reported cash flow data, KYMR recorded zero dividends and zero share repurchases across all ten quarters, with acquisition spending unavailable, indicating that all capital is retained to fund research operations.

The absence of distributions is consistent with a company in clinical development that must preserve liquidity against a persistent operating deficit. Stock-based compensation of roughly $14M to $19M per quarter is a non-cash cost that partially cushions reported cash burn, but it also implies ongoing dilution pressure. Future capital needs will likely depend on external financing, and investors should monitor the terms of any such raise.

Stock Compensation Flatters the Burn Picture

Based on reported figures, KYMR's stock-based compensation of $13.8M to $18.9M per quarter is added back in operating cash flow, meaning the cash burn would appear materially larger if equity pay were settled in cash.

Treating SBC as a non-cash add-back is standard, but it obscures the real economic cost borne by shareholders through dilution. Because the company has no positive free cash flow to offset it, the add-back effectively shifts burden from the income statement to the share count. The analytical concern is that the apparent cash discipline may partly reflect equity-funded compensation rather than sustainable operating efficiency.

KYMR — Frequently Asked Questions

Quick answers to the most common questions about buying KYMR stock.

How much cash does Kymera Therapeutics, Inc. (KYMR) generate from operations?

Kymera Therapeutics, Inc. (KYMR) generated $-232.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Kymera Therapeutics, Inc.'s free cash flow?

Kymera Therapeutics, Inc. (KYMR) reported negative free cash flow of $234.3M in 2025, indicating capital requirements exceeded cash from operations.

What is Kymera Therapeutics, Inc.'s capital expenditure (CapEx)?

Kymera Therapeutics, Inc. (KYMR) spent $1.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.